mRNA delivery in cancer immunotherapy.
10.1016/j.apsb.2023.03.001
- Author:
Yichen ZHONG
1
;
Shi DU
1
;
Yizhou DONG
1
Author Information
1. Division of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
- Publication Type:Review
- Keywords:
Cancer immunotherapy;
Lipid nanoparticles;
Lipid–polymer hybrid nanoparticles;
Messenger RNA;
Polymeric nanoparticles;
Protein/peptide-mediated nanoparticles;
mRNA delivery
- From:
Acta Pharmaceutica Sinica B
2023;13(4):1348-1357
- CountryChina
- Language:English
-
Abstract:
Messenger RNA (mRNA) has drawn much attention in the medical field. Through various treatment approaches including protein replacement therapies, gene editing, and cell engineering, mRNA is becoming a potential therapeutic strategy for cancers. However, delivery of mRNA into targeted organs and cells can be challenging due to the unstable nature of its naked form and the low cellular uptake. Therefore, in addition to mRNA modification, efforts have been devoted to developing nanoparticles for mRNA delivery. In this review, we introduce four categories of nanoparticle platform systems: lipid, polymer, lipid-polymer hybrid, and protein/peptide-mediated nanoparticles, together with their roles in facilitating mRNA-based cancer immunotherapies. We also highlight promising treatment regimens and their clinical translation.
